Core Viewpoint - The recent activities of China Biologic Products Holdings, including share buybacks and significant investments by the chairman, indicate strong confidence in the company's growth trajectory and international expansion plans [1] Group 1: Shareholder Activities - The chairman of China Biologic Products, Xie Qirun, increased his stake by acquiring 1.748 million shares at an average price of HKD 5.73, totaling an investment of HKD 10.016 million [1] - Since March 27, the company has spent over HKD 80 million on share buybacks, including the repurchase of 5.35 million shares for HKD 31.4377 million and 10 million shares for HKD 58.424 million [1] Group 2: Financial Performance - In 2025, the company reported revenue of RMB 31.83 billion, reflecting a year-on-year growth of 10.3%, and an adjusted net profit of RMB 4.54 billion, which is a 31.4% increase [1] - Revenue from new products saw a significant increase of 26.2% year-on-year, highlighting the success of the company's innovation efforts [1] Group 3: Future Outlook - Xie Qirun stated that the company has achieved double-digit growth in both revenue and net profit for four consecutive reporting periods, validating its long-term efforts in innovative drug development and strategic partnerships [1] - The year 2026 is anticipated to be a pivotal year for the company's internationalization, with recent licensing agreements marking a milestone and opening up substantial global valuation opportunities for its innovation pipeline [1]